This phase of the strategic planning process involved discussions with the research community in a series of 23 Working Group meetings.  Each meeting resulted in a final report.

	Cardiovascular #1: Coronary Artery Disease and Atherosclerosis
	Cardiovascular #2: Heart Failure and Cardiomyopathy
	Cardiovascular #3: Arrhythmias
	Cardiovascular #4: Vascular Diseases and Hypertension
	Cardiovascular #5: Valvular and Congenital Heart Diseases
	Cardiovascular #6: Regenerative and Reparative Medicine
	Cardiovascular #7: Emerging and Evolving Technologies
	Cardiovascular #8: From Discovery to Clinical Application
	Cardiovascular #9: Translation, Implementation, and Community Research
	Cardiovascular #10: Personalized Medicine Planning
	Cardiovascular #11: Bioinformatics and Computational Biology
	Cardiovascular #12: Clinical Trials Methodology
	Lung #1: Development and Early Origins of Disease
	Lung #2: Integrative Approaches to Pathogenic Research
	Lung #3: Inflammation/Injury; Remodeling, Repair and Replacement
	Lung #4: Personalized Medicine
	Lung #5: Enabling Therapeutic Trials and Translational Research
	Lung #6: New Investigation Workshop
	Blood #1: Critical Role of Inflammation in Ischemic Disorders
	Blood #2: Diagnosis and Treatment of Thrombotic Disorders
	Blood #3: Cellular Therapeutics
	Blood #4: Global Blood Safety and Availability
	Blood #5: Acquired and Inherited Blood Diseases

The Institute also convened a planning conference, The Future of Cardiovascular Disease: Today's Decisions...Tomorrow's Outcomes, on September 20, 2006. Its purpose was to explore the development of a national knowledge network to narrow the gaps between research discovery and application.